Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2023

Estudo comparativo de mundo real sobre a eficácia dos inibidores da Janus Quinase em pacientes com artrite reumatoide: O estudo de coorte ANSWER

Rheumatology 2023 doi 10.1093/rheumatology/kead543

Maeda T,

Okano T,

Ueda Y,

Fujii T,

Hata K,

Yoshikawa A,

Ebina K,

Etani Y,

Amuro H,

Hara R,

Okano T,

This multicentre, retrospective study by Hayashi, et al. found no significant differences in efficacy and safety between tofacitinib, baricitinib, peficitinib and upadacitinib in patients with RA. Predictive factors for resistance to LDA achievement included baseline CRP and CDAI for tofacitinib and baseline glucocorticoid dose, baseline CDAI and number of previous b/tsDMARDs for baricitinib.

Keywords:

July 2020

Retenção do Fármaco com 7 biológicos e tofacitinib em pacientes com artrite reumatóide naive para biológicos eem pacientes que trocaram de biológicos: o estudo de coorte ANSWER

Arthritis Res Ther 2020;22:142

Ebina K,

Maeda Y,

Shiba H,

Son Y,

Amuro H,

Hara R,

This paper is based upon a long-term cohort study, namely the ANSWER cohort, an observational multi-centre registry of RA patients in the Kansai district of Japan. Analyses demonstrate a difference in observed drug retention between bDMARDs-naïve and bDMARDs-switched patients. 7 bDMARD treatments were compared in patients with no prior exposure to biologics, with abatacept showing the greatest retention rate. In patients that had switched between these same bDMARDs or to tofacitinib throughout t...